Premium
Transjugular intrahepatic portosystemic shunts: an update
Author(s) -
Rosado Barbara,
Kamath Patrick S.
Publication year - 2003
Publication title -
liver transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.814
H-Index - 150
eISSN - 1527-6473
pISSN - 1527-6465
DOI - 10.1053/jlts.2003.50045
Subject(s) - medicine , transjugular intrahepatic portosystemic shunt , portal hypertension , liver transplantation , hepatorenal syndrome , hepatic encephalopathy , portal hypertensive gastropathy , ascites , cirrhosis , surgery , shunt (medical) , hydrothorax , portosystemic shunt , paracentesis , stent , transplantation , radiology , esophageal varices
Transjugular intrahepatic portosystemic shunts (TIPS) have been used in the treatment of complications of portal hypertension. TIPS is used for the control of acute variceal bleeding and for the prevention of vericeal rebleeding when pharmacologic therapy and endoscopic therapy have failed. Patients with refractory ascites with adequate hepatic reserve and renal function who fail to respond to large volume paracentesis may be reasonable candidates for TIPS. Promising indications for TIPS are Budd‐Chiari syndrome uncontrolled by medical therapy, severe portal hypertensive gastropathy, refractory hepatic hydrothorax, and hepatorenal syndrome. TIPS cannot be recommended for preoperative portal decompression solely to facilitate liver transplantation. Special care should be taken to insure proper placement of the stent to avoid increasing the technical difficulty of the transplantation procedure. The major limiting factors for TIPS success are shunt dysfunction and hepatic encephalopathy. Because shunt stenosis is the most important cause of recurrent complications of portal hypertension, a surveillance program to monitor shunt patency is mandatory. The MELD score may be useful in predicting post‐TIPS survival, and also in counseling patients and their families.